TransMedics Group (NASDAQ:TMDX) Shares Gap Down – Should You Sell?

TransMedics Group, Inc. (NASDAQ:TMDX)’s share price gapped down prior to trading on Tuesday . The stock had previously closed at $64.22, but opened at $61.32. TransMedics Group shares last traded at $63.35, with a volume of 215,169 shares.

Wall Street Analysts Forecast Growth

Several research analysts have commented on TMDX shares. Canaccord Genuity Group reduced their price objective on TransMedics Group from $109.00 to $104.00 and set a “buy” rating on the stock in a report on Wednesday, November 20th. Baird R W raised shares of TransMedics Group to a “strong-buy” rating in a report on Tuesday, September 24th. TD Cowen cut their price objective on shares of TransMedics Group from $175.00 to $120.00 and set a “buy” rating on the stock in a report on Monday, November 18th. Robert W. Baird lowered their target price on shares of TransMedics Group from $150.00 to $120.00 and set an “outperform” rating for the company in a research note on Wednesday, December 11th. Finally, Piper Sandler cut their price objective on TransMedics Group from $110.00 to $90.00 and set an “overweight” rating on the stock in a report on Wednesday, December 11th. Three equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $122.70.

TransMedics Group Trading Up 2.3 %

The firm’s 50-day simple moving average is $94.37 and its 200 day simple moving average is $130.78. The stock has a market cap of $2.21 billion, a P/E ratio of 68.32 and a beta of 2.06. The company has a current ratio of 8.20, a quick ratio of 7.33 and a debt-to-equity ratio of 2.42.

TransMedics Group (NASDAQ:TMDX) last posted its quarterly earnings results on Monday, October 28th. The company reported $0.12 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.29 by ($0.17). TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. The business had revenue of $108.76 million during the quarter, compared to analyst estimates of $115.00 million. During the same quarter last year, the firm posted ($0.12) EPS. The company’s quarterly revenue was up 63.7% compared to the same quarter last year. As a group, equities research analysts anticipate that TransMedics Group, Inc. will post 1 earnings per share for the current year.

Insider Activity

In other news, CEO Waleed H. Hassanein sold 8,625 shares of the company’s stock in a transaction dated Tuesday, October 15th. The shares were sold at an average price of $132.71, for a total transaction of $1,144,623.75. Following the completion of the transaction, the chief executive officer now owns 61,643 shares of the company’s stock, valued at approximately $8,180,642.53. This represents a 12.27 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Tamer I. Khayal sold 2,958 shares of the business’s stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $148.24, for a total transaction of $438,493.92. Following the completion of the sale, the insider now directly owns 20,843 shares in the company, valued at $3,089,766.32. This trade represents a 12.43 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 19,417 shares of company stock worth $2,240,738. 7.00% of the stock is owned by corporate insiders.

Institutional Trading of TransMedics Group

Several hedge funds have recently modified their holdings of TMDX. Wilmington Savings Fund Society FSB bought a new position in TransMedics Group during the 3rd quarter worth approximately $149,000. Sanctuary Advisors LLC lifted its position in TransMedics Group by 63.4% in the 3rd quarter. Sanctuary Advisors LLC now owns 4,041 shares of the company’s stock valued at $634,000 after acquiring an additional 1,568 shares in the last quarter. Morse Asset Management Inc acquired a new position in TransMedics Group in the 3rd quarter worth $823,000. Virtu Financial LLC bought a new position in shares of TransMedics Group during the third quarter worth about $436,000. Finally, Neo Ivy Capital Management acquired a new stake in shares of TransMedics Group in the third quarter valued at approximately $554,000. 99.67% of the stock is owned by institutional investors.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.